Exposure and schedule dependency of etoposide in neuroblastoma and leukaemia cells in vitro
- 31 December 1995
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (4) , 622-626
- https://doi.org/10.1016/0959-8049(95)00026-f
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer.Journal of Clinical Oncology, 1993
- Prolonged oral etoposide in small cell lung cancerAnnals of Oncology, 1993
- Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma.Journal of Clinical Oncology, 1991
- Instability of the anticancer agent etoposide under in vitro culture conditionsCancer Chemotherapy and Pharmacology, 1991
- Clinical pharmacodynamics of continuous-infusion etoposideCancer Chemotherapy and Pharmacology, 1990
- In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapyCancer Chemotherapy and Pharmacology, 1987
- Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratomaCancer Chemotherapy and Pharmacology, 1985
- Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assayCancer Chemotherapy and Pharmacology, 1985
- In vitro cytotoxicity of VP 16 on primary tumor and metastasis of Lewis lung carcinomaEuropean Journal of Cancer and Clinical Oncology, 1982
- Pharmacokinetics of VP16-213 given by different administration methodsCancer Chemotherapy and Pharmacology, 1982